OsteoSee uses its proprietary pEIT-based products to address the enormous unmet need of screening and diagnosing osteoporosis at the point-of-care, and monitoring treatment effect in the home environment.

​Clinical Problem / Unmet Need
According to the International Osteoporosis Foundation (IOF), 1 in 3 women and 1 in 5 men are at risk of an osteoporotic fracture. Approximately 9 million osteoporotic fractures occur annually worldwide. According to the World Health Organization (WHO), Osteoporosis is second only to cardiovascular disease as a global healthcare problem and medical studies show a 50-year-old woman has a similar lifetime risk of death from hip fracture as from breast cancer.
>70% of people at risk of osteoporosis have never been diagnosed or screened. Primary care physicians, where most people get care, are rarely part of the diagnosis and treatment process.

​Proposed Solution
Using OsteoSee’s unique parametric Electrical Impedance Tomography (pEIT),  (i) a tabletop system addresses the enormous unmet need of screening and diagnosing osteopenia and osteoporosis at the point-of-care, including at primary care physicians’ clinics; and (ii) for the first time, a wristband system connected to a smartphone enabling monitoring of osteoporosis treatment and potential drug-induced osteoporosis anywhere, including the home.

Ongoing clinical trial at two sites with over 500 subjects already scanned. 
An issued US patent with additional pending patent applications.
More Projects Funded
eHealth Ventures by Numbers:
Portfolio Companies
Companies Reviewed
Years of experience for 4 principles
Fair Value Appreciation on Portfolio
Partners & Collaborators